You have full text access to this OnlineOpen article

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

  1. Michele Follen M.D., Ph.D.1,†,*,
  2. Frank L. Meyskens Jr. M.D.2,
  3. Ronald D. Alvarez M.D.3,
  4. Joan L. Walker M.D.4,
  5. Maria C. Bell M.D.5,
  6. Karen Adler Storthz Ph.D.6,
  7. Jagannadha Sastry Ph.D.7,
  8. Krishnendu Roy Ph.D.8,
  9. Rebecca Richards-Kortum Ph.D.8,
  10. Terri L. Cornelison M.D., Ph.D.9

Article first published online: 22 OCT 2003

DOI: 10.1002/cncr.11674

Issue

Cancer

Cancer

Special Issue: Proceedings of the Second International Conference on Cervical Cancer

Supplement: Second International Conference on Cervical Cancer

Volume 98, Issue Supplement S9, pages 2044–2051, 1 November 2003

Additional Information

How to Cite

Follen, M., Meyskens, F. L., Alvarez, R. D., Walker, J. L., Bell, M. C., Adler Storthz, K., Sastry, J., Roy, K., Richards-Kortum, R. and Cornelison, T. L. (2003), Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer, 98: 2044–2051. doi: 10.1002/cncr.11674

Author Information

  1. 1

    Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Chao Family Comprehensive Cancer Center, Orange, California

  3. 3

    University of Alabama Medical Center, Birmingham, Alabama

  4. 4

    Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  5. 5

    Obstetrics & Gynecology Ltd., Sioux Valley Hospital, University of South Dakota Medical Center, Sioux Falls, South Dakota

  6. 6

    Department of Basic Sciences, The University of Texas Health Sciences Center at Houston Dental Branch, Houston, Texas

  7. 7

    Department of Veterinary Sciences, The University of Texas M. D. Anderson Cancer Center Science Park, Bastrop, Texas

  8. 8

    Department of Biomedical Engineering, The University of Texas, Austin, Texas

  9. 9

    Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland

  1. †

    Fax: (713) 792-4856

*Center for Biomedical Engineering, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 193, Houston, TX 77030

Publication History

  1. Issue published online: 22 OCT 2003
  2. Article first published online: 22 OCT 2003
  3. Manuscript Accepted: 21 JAN 2003
  4. Manuscript Received: 31 OCT 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (883K)

REFERENCES

  • 1
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114–2119.
  • 2
    Mitchell MF, Hittelman WK, Lotan R, et al. Chemoprevention trials and surrogate end point biomarkers in the cervix [review]. Cancer. 1995; 76(Suppl): 1956–1977.
    Direct Link:
  • 3
    Follen M, Meyskens FL, Atkinson EN, Schottenfeld D. Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. J Natl Cancer Inst. 2001; 93: 1293–1296.
  • 4
    Follen M, Vlastos A-T, Meyskens FL, Atkinson EN, Schottenfeld D. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control. 2002; 13: 855–873.
  • 5
    Romney SL, Dwyer A, Slagle S, et al. Chemoprevention of cervix cancer: Phase I-II. A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol. 1985; 20: 109–119.
  • 6
    Surwit EA, Graham V, Droegemueller W, et al. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol. 1982; 143: 821–823.
  • 7
    Meyskens FL Jr., Graham V, Chvapil M, et al. A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst. 1983; 71: 921–925.
  • 8
    Weiner SA, Surwit EA, Graham VE, et al. A phase I trial of topically applied trans-retinoic acid in cervical dysplasia—clinical efficacy. Invest New Drugs. 1986; 4: 241–244.
  • 9
    Graham V, Surwit ES, Weiner S, Meyskens FL. Phase II trial of β-ALL-trans-retinoic acid for cervical intraepithelial neoplasia via collagen sponge and cervical cap. West J Med. 1986; 145: 192–195.
  • 10
    Meyskens FL Jr., Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994; 86: 539–543.
  • 11
    Current Clinical Trials Oncology. Protocol 13869. National Cancer Institute PDQ. 2000; 7(1).
  • 12
    Follen M, Atkinson EA, Schottenfeld D, et al. A randomized clinical trial of 4-HPR for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res. 2001; 11: 3356–3365.
  • 13
    Alvarez RD, Conner MG, Weiss HL, et al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double blind clinical trial. Cancer Epidemiol Biomarkers Prev. 2003; 12: 114–119.
  • 14
    Romney SL, Basu J, Vermund S, Palan P, Duttagupta C. Plasma reduced and total ascorbic acid in human uterine cervix dysplasias and cancer. Ann N Y Acad Sci. 1987; 498: 132–143.
    Direct Link:
  • 15
    Current Clinical Trials Oncology. Protocol 09315. National Cancer Institute PDQ. 1994; 1(2).
  • 16
    Romney SL, Ho GYF, Palan PR, et al. Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol. 1997; 65: 483–492.
  • 17
    Manetta A, Schubbert T, Chapman J, et al. β-carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev. 1996; 5: 929–932.
  • 18
    Current Clinical Trials Oncology. Protocol 09088. National Cancer Institute PDQ. 1994; 1(2).
  • 19
    Keefe KA, Schell MJ, Brewer C, et al. A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1998; 10: 1029–1035.
  • 20
    De Vet HCW, Knipschild PG, Willebrand D, Schouten HJA, Sturmans F. The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment. J Clin Epidemiol 1991; 44: 273–283.
  • 21
    Fairley CK, Tabrizi SN, Chen S, et al. A randomized clinical trial of beta carotene vs. placebo for the treatment of cervical HPV infection. Int J Gynecol Cancer. 1996; 6: 225–230.
    Direct Link:
  • 22
    Mackerras D, Irwig L, Simpson JM, et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer. 1999; 79: 1448–1453.
  • 23
    Butterworth CE, Hatch KD, Soong SJ, Cole P, Tamura T, Sauberlich HE. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol. 1992; 166: 803–809.
  • 24
    Butterworth CE Jr., Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA. 1992; 267: 528–533.
  • 25
    Childers JM, Chu J, Voigt LF, et al. Chemoprevention of cervical cancer with folic acid: a phase II Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev. 1995; 4: 155–159.
  • 26
    Mitchell MF, Tortolero-Luna G, Lee JJ, et al. Phase I dose de-escalation trial of α-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res. 1998; 4: 303–310.
  • 27
    Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol. 2000; 78: 123–129.
  • 28
    Follen M, Schottenfeld D. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials. Cancer. 2001; 91: 1758–1776.
    Direct Link:
  • 29
    Gissman L, Osen W, Muller M, Jochmus I. Therapeutic vaccines for human papillomaviruses. Intervirology. 2001; 44: 167–175.
  • 30
    Lehniten M, Paavonene J. Efficacy of preventive human papillomavirus vaccination. Int J STD AIDS. 2001; 12: 771–776.
  • 31
    Im SS, Monk BJ, Villarreal LP. Prevention of cervical cancer with vaccines. Curr Oncol Rep. 2001; 3: 322–328.
  • 32
    Lowy DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr. 1998; 23: 27–30.
  • 33
    Diaz-Arrastia C, Arany I, Rabazetti SC, et al. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res. 2001; 7: 3031–3033.
  • 34
    Apgar BS. Changes in strategies for human papillomavirus genital disease. Am Fam Physician. 1997; 55: 1545–1546, 1548.
  • 35
    Andrei G, Snoeck R, Piette J, DeIvenne P, DeClercq E. Inhibiting effects of ciofovir (HPMPC) on growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res. 1998; 10: 533–539.
  • 36
    Van Cutsem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol. 1995; 45: 230–235.
    Direct Link:
  • 37
    Abdullkarim B, Sabri S, Deutsch E, et al. Antiviral agent Ciofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene. 2002; 21: 2334–2346.
  • 38
    Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir. A new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol. 2000; 60: 205–209.
    Direct Link:
View Full Article (HTML) Get PDF (883K)